Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: EGIS-11150
Mode of action: D2R antagonist with effect on adrenergic and serotonergic receptors
Phase: Preclinical

Useful Links:

Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG, Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology . 2013 Jan ; 64():254-63. Abstract

July 26, 2016
SRF News
SRF Comments
Text Size
Reset Text Size

Check out our upcoming webinar, Studying Psychosis in 22q11 Deletion Syndrome, Thursday, July 28, 2016, 1-2:30 p.m. EDT.

See our recent webinar, The Baby and the Bathwater: Signal and Noise in Psychiatric Neuroimaging.
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright